The convergence of AI, decentralized technologies, behavioral science, and real-world evidence opens the door to a new era in which the clinical trial industry proactively addresses participation barriers, integrates social determinants of health, and reimagines patient centricity.
In this video interview, Heather Horville, solutions consultant at Greenphire, discusses how clinical teams can boost participant retention in lengthy or complex trials through strategies like personalized engagement, stipends tied to ePRO diaries, and concierge services that offer one-to-one human connection.
How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.
Why future-ready pharma companies must embrace AI-driven, real-time decision-making.
AI as an accelerator for data-centric, process-centric, and human-centric clinical research.
As clinical research increasingly relies on RWD to enhance trial design and patient insights, tokenization has emerged as a critical solution for securely linking disparate datasets while protecting patient privacy.
How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
As wearable ECG technology advances, cardiac safety studies in clinical trials are evolving to capture richer, continuous heart data while reducing patient burden.
In this Q&A, Megan Bailey, EVP and president of central laboratories and international, Labcorp, discusses how central labs are evolving beyond testing to become strategic partners in clinical trial success.
In this video interview, Matt Robinson, PhD, senior director, oncology research program, National Comprehensive Cancer Network (NCCN), explores how emerging technologies such as wearable devices, real-world data analysis, and decentralized trial designs can improve the identification and engagement of potential cancer clinical trial participants.
Overcoming hurdles with licensing complexities, post-production changes, and IRB submissions can help in reducing timelines and increasing collaboration.
Strategies for ensuring that innovation with PROs remains parallel with advancements in disease detection and progression.
Addressing data integrity and compliance concerns.
Pilot trial shows that a user-friendly electronic patient-reported outcome (ePRO) monitoring system significantly improves patient-centered cardiovascular care by enhancing patient-physician communication, increasing clarity in treatment explanations, and empowering patients with better knowledge of their conditions.
Get ready for ACT's upcoming Peer Exchange about the electronic elements of a clinical trial.
Using surveys to collect various viewpoints on eConsent from ethics, sponsors, and vendors.
A use case by Memorial Sloan Kettering Cancer Center explores the potential of EHR-to-EDC.
Five industry leaders share their perspectives on the evolution of DCTs.
Designing eConsent for each study from a stakeholders’ value, not technology perspective.
After a period of "fits and starts," large pharma companies are increasingly investing in digital health tools to reach business goals, be they through internal investments or strategic partnerships.
Key considerations in deploying fit-for-purpose digital health technologies in drug development.
Factors that contribute to Japan's prominent position in the rapidly evolving field of digital therapeutics and why it matters to the global life sciences industry.
Harnessing advances in digital health technologies for a more precision-measured approach.
Harnessing these tools for successful integration and streamlining of processes.
An increasing number of patients report looking for more simplicity and less burden related to a clinical trial, and a "bring your own device" option is one of the ways to meet this need
Fostering common eConsent terminologies enriches communication and understanding across all stakeholders.
